Molecular structure of Ceralasertib, CAS Number: 1352226-88-0
Ceralasertib (CAS 1352226-88-0)
Alternate Names:
AZD6738 AZD 6738 AZD-6738 CHEMBL4285417
CAS Number:
1352226-88-0
Molecular Weight:
412.50
Molecular Formula:
C20H24N6O2S
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
QUICK LINKS
Ordering Information
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Ceralasertib (CAS 1352226-88-0) References
- A Mathematical Model to Investigate the Effects of Ceralasertib and Olaparib in Targeting the Cellular DNA Damage Response Pathway. | Pugh, K., et al. 2023. J Pharmacol Exp Ther. 387: 55-65. PMID: 37391224
- Chronic treatment with ATR and CHK1 inhibitors does not substantially increase the mutational burden of human cells. | Casimir, L., et al. 2023. Mutat Res. 827: 111834. PMID: 37531716
- Biomarker-driven phase 2 umbrella trial: Clinical efficacy of olaparib monotherapy and combination with ceralasertib (AZD6738) in small cell lung cancer. | Park, S., et al. 2024. Cancer. 130: 541-552. PMID: 37843249
- Proteomic and phosphoproteomic analysis of responses to enterovirus A71 infection reveals novel targets for antiviral and viral replication. | Lin, D., et al. 2023. Antiviral Res. 220: 105761. PMID: 37992763
- The ATR inhibitor elimusertib exhibits anti-lymphoma activity and synergizes with the PI3K inhibitor copanlisib. | Sartori, G., et al. 2024. Br J Haematol. 204: 191-205. PMID: 38011941
- Targeted inhibition of the ATR/CHK1 pathway overcomes resistance to olaparib and dysregulates DNA damage response protein expression in BRCA2MUT ovarian cancer cells. | Biegała, Ł., et al. 2023. Sci Rep. 13: 22659. PMID: 38114660
- MGMT function determines the differential response of ATR inhibitors with DNA-damaging agents in glioma stem cells for GBM therapy. | Leong, VWS., et al. 2024. Neurooncol Adv. 6: vdad165. PMID: 38213834
- The ATR inhibitor ceralasertib potentiates cancer checkpoint immunotherapy by regulating the tumor microenvironment. | Hardaker, EL., et al. 2024. Nat Commun. 15: 1700. PMID: 38402224
- The Novel ATR Inhibitor M1774 Induces Replication Protein Overexpression and Broad Synergy with DNA-targeted Anticancer Drugs. | Jo, U., et al. 2024. Mol Cancer Ther. 23: 911-923. PMID: 38466804
- Multidrug resistance transporters P-gp and BCRP limit the efficacy of ATR inhibitor ceralasertib in cancer cells. | Chen, XY., et al. 2024. Front Pharmacol. 15: 1400699. PMID: 38756373
Inhibitor of:
4931417G12Rik, AK7, APLF, Aprataxin, ATR, BABAM1, BRCAA1, C12orf12, C20orf196, C20orf43, DCAR, Dclre1c, DNA Ligase I, EG546272, EG546282, Etaa1, FAAP24, GBDR1, IL-11, Las17, Mec1, MUS81, PALB2, PAR4, PARP-7, PIERCE 1, Rad17, Rad24, Rad3, RECA-1, REV1, RFWD3, RNase HII-A, SmarcAL1, SMC1β, TdTIF1 (DNTTIP1), TEX38, TGIF2LX1, TopBP1, TRABID, TRF2, VPRBP, and ZRANB3.Activator of:
ATDC, DNA pol θ, DNAH5, Etaa1, FAM111A, FANCD2, FANCM, ORC2_Orc2, PRIM2A, Rad1, Rad18, and ZSWIM7.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Ceralasertib, 10 mg | sc-507439 | 10 mg | $573.00 |